2018年、ミリマンのウェブサイトに発表された記事およびレポートで最も読まれたトピックスは、今年もヘルスケアでした。処方薬コスト、オピオイドの蔓延、医療費負担適正化法の個人向け市場などについてミリマンのコンサルタントが書いたものです。中でも最も読まれたのは、5月に発表されたミリマン・メディカル・インデックスに関するレポートです。それに大きく引き離されることなく読まれたのは、年金関連の記事で、毎月のペンション・ファンディング・インデックスと、毎年のコーポレート・ペンション・ファンディング調査です。またトップ10のリストのうち2つは、オーストラリアの退職に関する記事でした。
Milliman Medical Index By Christopher Girod, Susan Hart, and Scott Weltz
In 2018, the cost of healthcare for a typical American family of four covered by an average employer-sponsored preferred provider organization (PPO) plan is $28,166.
Pension Funding Index (by Charles J. Clark and Zorast Wadia) and 2018 Corporate Pension Funding Study (By Zorast Wadia, Alan H. Perry, and Charles J. Clark)
Monthly reports on the funded status of the 100 largest corporate defined benefit pension plans as measured by the Milliman 100 Pension Funding Index.
2018 Corporate Pension Funding Study
During 2017, the private single-employer defined benefit plans of the Milliman 100 companies made significant funding improvements.
A primer on prescription drug rebates: Insights into why rebates are a target for reducing prices By Gabriela Dieguez, Maggie Alston, Samantha Tomicki
For brand-name prescription drugs in competitive therapeutic classes, rebates are often the deciding factor when health insurers choose how to cover a drug, and how much a patient should pay for it.
Figure 2: Rebates in the prescription drug distribution chain
How will the Bipartisan Budget Act of 2018 impact Part D in 2019 and beyond? By Adam Barnhart, Gabriela Dieguez, David R. Mike
The Bipartisan Budget Act of 2018, passed in February, enacted key changes to the Medicare Part D program that will impact the “donut hole” starting in 2019.
Five ways the Amazon / Berkshire Hathaway / JPMorgan Chase deal could change healthcare in the U.S.
Amazon, Berkshire Hathaway, and JPMorgan Chase announced their intent to pursue the formation of an independent healthcare company “free from profit-making incentives and constraints.” While the announcement of this partnership brought excitement to many within the industry, there are still many details to be ironed out and much uncertainty around what issues the group will tackle first.
The individual mandate repeal: Will it matter? By Fritz Busch, Paul R. Houchens
With the passage of the Tax Cuts and Jobs Act of 2017, there are renewed concerns related to the stability of the individual market.
Figure 1: 2017 APTC Eligibility and Affordability Exemptions: Single Household, Based on National Average Bronze Premium
Opioid use disorder in the United States: Diagnosed prevalence by payer, age, sex, and state By Stoddard Davenport and Katie Matthews
Over 25 million American adults report suffering from daily chronic pain. The increasing use of opioids in recent years has taken a human toll, leading to a rising number of overdose deaths and diagnoses of opioid use disorder.
Surprising new research reveals the majority of Australian retirees spend less than the Government Age Pension By Jeff Gebler
New research suggests mandatory and voluntary measures to boost super may not be enough to produce improved retirement lifestyles without a deeper understanding of the motivations driving retiree behaviour.
2018 summary of individual market enrollment and Affordable Care Act subsidies By Paul R. Houchens, Jason A. Clarkson, Zachary Fohl
Our second annual profile of the individual health insurance market for each state along with the District of Columbia.
Analysis: Retirees’ spending falls faster than expected into old age By Jeff Gebler
According to a Milliman analysis, the financial services industry may have underestimated the dramatic falloff in retiree spending as retirees age.